F
Frank W. Lee
Researcher at Millennium Pharmaceuticals
Publications - 21
Citations - 3719
Frank W. Lee is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Pharmacokinetics & In vivo. The author has an hindex of 13, co-authored 21 publications receiving 3553 citations.
Papers
More filters
Journal ArticleDOI
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Dennis Huszar,Catherine A. Lynch,Victoria Fairchild-Huntress,Judy H. Dunmore,Qing Fang,Lucy R Berkemeier,Wei Gu,Robert A. Kesterson,Bruce A. Boston,Roger D. Cone,Françoise J. Smith,L. Arthur Campfield,Paul Burn,Frank W. Lee +13 more
TL;DR: The data identify a novel signaling pathway in the mouse for body weight regulation and support a model in which the primary mechanism by which agouti induces obesity is chronic antagonism of the MC4-R.
Journal ArticleDOI
Strategy of Utilizing In Vitro and In Vivo ADME Tools for Lead Optimization and Drug Candidate Selection
TL;DR: Applications of the available ADME tools are discussed to better understand the clinical implication of these properties, and to optimize these properties.
Journal ArticleDOI
Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
TL;DR: In vitro inhibition of various expressed p450s upon 30-min preincubation with ABT showed that CYP1A2, 2B6,2C9, 2C19, 2D6, and 3A4 were inhibited in a dose-dependent manner, and the intravenous pharmacokinetics of AP also was affected in adose- dependent manner in all species.
Journal ArticleDOI
A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery.
TL;DR: The experiments in this work demonstrate that the LC/MS/MS-based depletion method can provide direct and accurate measurement of RBC partitioning for compounds in drug discovery.
Patent
Screening methods for compounds useful in the regulation of body weight
TL;DR: In this paper, drug screening assays and diagnostic and therapeutic methods for the treatment of body weight disorders, such as obesity, anorexia and cachexia, utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention.